Arcus biosciences Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Arcus biosciences Contact Number

Contact Arcus Biopharmaceutical Company Cancer Therapies …

2 hours ago Arcusbio.com Show details

Arcus Biosciences address is 3928 Point Eden Way Hayward, CA 94545. Contact/Email us for investor, media and business development or partnering inquiries.

Category: Contact SupportShow more

Arcus Biosciences Crunchbase

7 hours ago Crunchbase.com Show details

510-694-6200

Phone Number +1 510-694-6200. Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical

Founder: Juan Jaen, Terry Rosen
Location: Hayward, California
Founded: Jan 01, 2015

Category: Contact NumberShow more

Contact Investor Relations Arcus Bio

7 hours ago Investors.arcusbio.com Show details

Contact Investor Relations. The following errors must be corrected. First Name is required. Last Name is required. Phone Number is required. Company Name is required. Country is required. Email Address is required. State/ Province is required.

Category: Contact SupportShow more

Arcus Biosciences Home Pursuit of Curing Cancer

1 hours ago Arcusbio.com Show details

(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners

Estimated Reading Time: 4 mins

Category: Home PhoneShow more

Investors & Media Contact Investor Relations FAQs Arcus Bio

5 hours ago Investors.arcusbio.com Show details

(800) 962-4284

Arcus's transfer agent is Computershare. Computershare Trust Company, N.A. 150 Royall Street. Canton, Massachusetts 02021. (800) 962-4284. back to top.

Category: Contact SupportShow more

Arcus Biosciences Email Format arcusbio.com Emails RocketReach

Just Now Rocketreach.co Show details

Arcus Biosciences Email Format. Arcus Biosciences uses 2 email formats, with first_initial last (ex. [email protected]) being used 97.0% of the time. Get Verified Emails for Arcus Biosciences Employees. Arcus Biosciences's Email Format. Percentage.

Category: Contact NumberShow more

Arcus Biosciences Company Profile Office Locations, …

4 hours ago Craft.co Show details

Arcus Biosciences has 83 employees at their 1 location and $1.41 M in annual revenue in FY 2017. See insights on Arcus Biosciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Scientific Advisory Board Arcus Biosciences

6 hours ago Arcusbio.com Show details

Since retiring from Amgen, he has assisted a number of private companies as a scientific advisor and independent director. Antoni Ribas, MD, PhD Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research to understand how the immune system can be used to treat cancer.

Category: Contact NumberShow more

Virtual Event October 2627 TIGIT Therapies

8 hours ago Tigit-therapies.com Show details

617 455 4188

Arcus Biosciences. Shyra Gardai. Executive Director. Seattle Genetics. Sandhya Girish. OUR CONTACT DETAILS. T: (+1) 617 455 4188. E: [email protected] Design and site by Event Engine Hanson Wade Limited is registered in England & Wales, number 06752216. Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.

Category: Contact NumberShow more

Arcus Biosciences Employees, Board Members, Advisors & …

4 hours ago Crunchbase.com Show details

Arcus Biosciences has 8 board members and advisors, including Yasunori Kaneko. Yasunori Kaneko Board Member. Blake Byers Board Observer 2016. Kristen Hege Board Member. Terry Rosen Board Member. Kathryn E. Falberg Board Member Feb 2014. Jennifer Jarrett Board Member. Juan Jaen Board Member. David Beier Board Member Dec 2017.

Category: Contact NumberShow more

Infinity Pharmaceuticals Crunchbase

4 hours ago Crunchbase.com Show details

617-453-1000

Contact Email [email protected] Phone Number 617-453-1000 Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies.

Category: Contact NumberShow more

Study to Evaluate Monotherapy Compared to Combination …

7 hours ago Clinicaltrials.gov Show details

You have reached the maximum number of saved studies (100). To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Arcus Biosciences, Inc. More Information.

Category: Contact NumberShow more

DROIA Investments, Portfolio & Company Exits Crunchbase

4 hours ago Crunchbase.com Show details

Number of Diversity Investments 2 DROIA has made 2 diversity investments. Their most recent diversity investment was on Nov 13, 2017 , when Arcus Biosciences raised $107M .

Category: Contact NumberShow more

Arcus Biosciences, Inc. (RCUS) Company Profile & Facts Yahoo

5 hours ago Finance.yahoo.com Show details

See the company profile for Arcus Biosciences, Inc. (RCUS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and

Category: Contact NumberShow more

A Study to Evaluate the Safety and Tolerability of AB680 in …

7 hours ago Clinicaltrials.gov Show details

Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0 [ Time Frame: From first dose date to 90 days after the last dose (approximately 1 year) ] Number of participants treated with AB680 in combination with Zimberelimab and nab-paclitaxel and gemcitabine with Treatment Emergent Adverse Events (TEAEs) as

Category: Contact NumberShow more

ARCUS BIOSCIENCES, INC. : Shareholders Board Members …

2 hours ago Marketscreener.com Show details

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs.

Category: Contact NumberShow more

Arcus Biosciences Number of Employees 20172021 RCUS …

4 hours ago Macrotrends.net Show details

Arcus Biosciences number of employees from 2017 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Arcus Biosciences is a biopharmaceutical company.

Category: Contact NumberShow more

Arcus Biosciences Inc RCUS DividendMax

6 hours ago Dividendmax.com Show details

0%. 2021. Sign Up Required. Arcus Biosciences Inc Optimized Dividend Chart. The chart below shows the optimized dividends for this security over a rolling 12 …

Category: Contact NumberShow more

Multiple Cancer Types Arcus Clinical Trials Enroll Now Arcus …

9 hours ago Arcusbio.com Show details

Overview. A Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab in participants with advanced malignancies.

Category: Contact NumberShow more

Investors & Media Press Releases Arcus Bio

8 hours ago Investors.arcusbio.com Show details

Press Releases. For new employee inducement grant announcement inquiries, please contact the company at [email protected]

Category: Contact NumberShow more

Daniel Direnzo Principal Investigator Arcus Biosciences …

8 hours ago Apollo.io Show details

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs.We are located in the San Francisco bay area, in

Category: Contact NumberShow more

Publications Conferences Arcus Biosciences

4 hours ago Arcusbio.com Show details

September 19-21, 2020. European Society for Medical Oncology (ESMO) Congress. ARC-4: Efficacy and Safety of Etrumadenant (AB928) plus Carboplatin, Pemetrexed and a PD-1 Antibody in Participants with Metastatic Non-Small Cell Lung Cancer. A Spira , et al. September 19-21, 2020.

Category: Contact NumberShow more

Arcus Biosciences Arcus Biosciences Announces Third Quarter …

2 hours ago Investors.arcusbio.com Show details

ARCUS BIOSCIENCES, INC. Consolidated Statements of Operations and Comprehensive Loss Weighted-average number of shares used to compute basic net income (loss) per share 62,599,193 43,939,281 Investor Contact. [email protected]

Category: Contact NumberShow more

Investors & Media Events & Presentations Corporate …

1 hours ago Investors.arcusbio.com Show details

View our Corporate Presentations on the Arcus Biosciences site and contact Investor Relations here.

Category: Contact NumberShow more

Arcus Biosciences Funding, Financials, Valuation & Investors …

6 hours ago Crunchbase.com Show details

Arcus Biosciences has raised a total of $647.1M in funding over 5 rounds. Their latest funding was raised on Feb 1, 2021 from a Post-IPO Equity round. Arcus Biosciences is registered under the ticker NYSE:RCUS . Their stock opened with $15.00 in its Mar 14, …

Category: Contact NumberShow more

Arcus Biosciences, Inc. (RCUS) Company Profile & Overview …

6 hours ago Stockanalysis.com Show details

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Category: Contact NumberShow more

Did Hedge Funds Make The Right Call On Arcus Biosciences, Inc. (RCUS) Yahoo

2 hours ago Finance.yahoo.com Show details

Arcus Biosciences, Inc. (NYSE:RCUS) was in 23 hedge funds' portfolios at the end of March. RCUS has experienced an increase in support from the world's most elite money managers lately.

Category: Contact NumberShow more

Arcus Biosciences, Inc., Jobs & Salary for Foreign Workers …

9 hours ago Myvisajobs.com Show details

Review. Arcus Biosciences, Inc. has filed 17 labor condition applications for H1B visa and 0 labor certifications for green card from fiscal year 2018 to 2020. Arcus Biosciences was ranked 11552 among all visa sponsors. Please note that 0 LCA for H1B Visa and 0 LC for green card have been denied or withdrawn during the same period. Contact

Category: Contact NumberShow more

Arcus Biosciences Arcus Biosciences Reports Second Quarter …

5 hours ago Investors.arcusbio.com Show details

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.

Category: Contact NumberShow more

Katherine Jensen Associate Director Regulatory Affairs CMC Arcus Biosciences …

2 hours ago Linkedin.com Show details

A dedicated and self-motivated professional with exceptional leadership abilities, and a comprehensive knowledge of 21CFR Parts 11, 210, 211, and 820, with an ability to convey complex information

Title: Associate Director Regulatory …
Location: Greater Denver
1. 500+ connections

Category: Contact NumberShow more

Dawn Colburn's email & phone number Executive Director of …

6 hours ago Signalhire.com Show details

View Dawn Colburn's email address: [email protected] & phone: +1-xxx-xxx-6489's profile as Executive Director of Clinical Science at Arcus Biosciences, located in San Mateo, California. Find contacts: direct phone number, email address, work experience.

Category: Phone NumberShow more

Taiho Ventures Investments, Portfolio & Company Exits …

5 hours ago Crunchbase.com Show details

Taiho Ventures has made 3 diversity investments. Their most recent diversity investment was on Jun 20, 2019, when Axial Biotherapeutics raised $10M. Taiho Ventures has had 5 exits. Taiho Ventures 's most notable exits include Arcus Biosciences , ORIC Pharmaceuticals , …

Category: Contact NumberShow more

What Do Analysts Say About Arcus Biosciences Inc. (RCUS)? – The …

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 69.75 million. RCUS does have institutional investors; and they hold 58.50% of the stock. Arcus Biosciences Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 7 new insider purchases involving 22,700 shares.

Category: Contact NumberShow more

Commercial Kitchen Equipment Perth WA Hospitality, Catering & …

5 hours ago Arcus.com.au Show details

(08) 9241 8888

Our service department runs 24 hours a day, 7 days a week, so our highly trained team are always at your call. To book a service, please call the following number and follow the menu through to service. (08) 9241 8888. To book or enquire about preventative maintenance or to simply make a general service enquiry, please e-mail us.

Category: Contact NumberShow more

Jennifer Jarrett VP, Corporate Development and Capital …

Just Now Crunchbase.com Show details

Number of Past Jobs 1 Jennifer Jarrett has 2 current jobs as VP, Corporate Development and Capital Markets at Uber and COO at Arcus Biosciences . Additionally, Jennifer Jarrett has had 1 past job as the CFO & COO at Arcus Biosciences .

Category: Contact NumberShow more

Precision BioSciences and iECURE Announce License and …

Just Now Investor.precisionbiosciences.com Show details

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with …

Category: Contact NumberShow more

Arcus Biosciences, Inc. (RCUS) CEO Terry Rosen on Q2 2021 …

7 hours ago Seekingalpha.com Show details

Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 ET Company Participants Katherine Bock - VP, IR & Corporate Strategy Terry Rosen -

Category: Contact NumberShow more

A Phase 1/1b Study to Evaluate the Safety and Tolerability of …

6 hours ago Hackensackumc.org Show details

Study ID Arcus BioSciences AB928CSP0003 . NCT Number NCT03720678 (Click on the NCT number for more information about the trial) . Research Study Number 2018-1042 . …

Category: Contact NumberShow more

Precision BioSciences and iECURE Announce License and …

Just Now Businesswire.com Show details

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS

Category: Contact NumberShow more

Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating …

8 hours ago Finance.yahoo.com Show details

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as

Category: Contact NumberShow more

Arcus Biosciences to Participate at Upcoming Investor Conferences

3 hours ago Finance.yahoo.com Show details

HAYWARD, Calif., September 01, 2021--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that

Category: Contact NumberShow more

Lilly and Precision BioSciences Announce Genome Editing …

3 hours ago Investor.precisionbiosciences.com Show details

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS ® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an …

Category: Contact NumberShow more

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical …

6 hours ago Investors.infi.com Show details

510-694-6261

Source: Arcus Biosciences. Arcus Biosciences Contacts: Jennifer Jarrett, 510-694-6261 [email protected] or Nicole Arndt, 510-284-4728 [email protected] or Infinity Pharmaceuticals Contact: Stern Investor Relations, Inc. Daniella Funaro, 212-362-1200 [email protected]

Category: Contact NumberShow more

Arcus Biosciences Reports First Quarter 2021 Financial Results and …

5 hours ago Finance.yahoo.com Show details

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, …

Category: Contact NumberShow more

Arcus Biosciences Inc. (RCUS): The long term indicators on the …

5 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 69.75 million. RCUS does have institutional investors; and they hold 58.50% of the stock. Arcus Biosciences Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 7 new insider purchases involving 22,700 shares.

Category: Contact NumberShow more

Arcus Biosciences Reports Second Quarter 2021 Financial Results …

6 hours ago Finance.yahoo.com Show details

HAYWARD, Calif., August 05, 2021--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial

Category: Contact NumberShow more

Insider Trading Activities at Arcus Biosciences, Inc. (RCUS)

5 hours ago Insider-monitor.com Show details

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arcus Biosciences, Inc. (RCUS) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Arcus Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1724521.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is arcus biosciences?

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

What are the clinical trials of arcus biosciences?

ARC-8: Phase 1/1b Study to Evaluate Safety and Tolerability of AB680 + Chemotherapy + Zimberelimab (AB122) in Patients with Treatment-Naive Metastatic Pancreatic Adenocarcinoma GA Manji, et al. ARC-9: Phase 1b/2 Study to Evaluate Etrumadenant (AB928)-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

What kind of cancer is arcus working on?

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.

What kind of service does arcus australia offer?

With bars, benching, canopies, trolleys and even wall panelling, our WA factory has stainless solutions for all! At Arcus Australia, we believe in good, old-fashioned quality products paired with high-quality service.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes